Dupixent topped Rx and over-the-counter (OTC) pharma brands for ad impressions during Q1 2025, according to data released by iSpot.tv on Monday afternoon. The Regeneron and Sanofi brand for asthma and ...
Tremfya snagged Dupixent’s place as the pharma brand with the most TV impressions in June, according to data released by iSpot.tv on Friday morning. The Johnson & Johnson brand garnered a 4.3% share ...
Hosted on MSN
Sanofi stock slides on Dupixent successor AD trial
Sanofi’s stock dropped in the wake of data from its Phase III trial of atopic dermatitis (AD) candidate amlitelimab, which had been touted as a potential successor to Dupixent. While the Phase III ...
(Reuters) -Regeneron Pharmaceuticals beat Wall Street estimates for third-quarter results on Tuesday, helped by strong demand for its eczema treatment, Dupixent, and cancer treatment Libtayo, sending ...
Regeneron Pharmaceuticals (REGN) and Sanofi (SNY) reported positive data from the late-stage trial, which assessed Dupixent ...
A Nektar Therapeutics drug has met the skin clearance goals of a closely watched mid-stage clinical trial in atopic dermatitis. While these preliminary results bring validation to the therapy’s novel ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback